BioVie (NASDAQ: BIVI) CMO boosts stake with open-market share buy

Q: What insider transaction did BIVI report for Joseph M. Palumbo?

BIOVIE INC. reported that Chief Medical Officer Joseph M. Palumbo purchased 4,843 shares of common stock on 2026-08-28 in open market transactions at $2.16 per share, increasing his directly held stake to 6,036 shares.

Q: Was the recent BIVI insider trade a buy or a sell?

The reported BIVI insider trade was a purchase. On 2026-08-28, Chief Medical Officer Joseph M. Palumbo bought 4,843 shares of BIOVIE INC. common stock at $2.16 per share in open market transactions.

Filing Impact

(Neutral)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

BIOVIE INC. (BIVI) reported that Chief Medical Officer Joseph M. Palumbo purchased common stock. On 2026-08-28 he bought 4,843 shares of common stock in open market transactions at $2.16 per share, bringing his directly held position to 6,036 shares.

The shares were acquired in several open market trades, all executed at the same price.

Insider Trade Summary

Net Buyer: 4,843 shares

Net Buy 1 txn

Insider Palumbo Joseph M

Role Chief Medical Officer

Bought 4,843 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Stock ^F1	4,843	$2.16	$10K

Holdings After Transaction: Common Stock — 6,036 shares (Direct)

Footnotes (1)

F1. The shares of Common Stock were purchased in several open market transactions, all at the same price. The reported price does not reflect a weighted average price.

Key Figures

Shares purchased: 4,843 shares of Common Stock Purchase price per share: $2.16 per share Shares owned after transaction: 6,036 shares of Common Stock +1 more

4 metrics

Shares purchased 4,843 shares of Common Stock Non-derivative open market purchase on 2026-08-28

Purchase price per share $2.16 per share Price for all reported open market transactions on 2026-08-28

Shares owned after transaction 6,036 shares of Common Stock Directly held by Joseph M. Palumbo following the 2026-08-28 purchase

Net buy shares 4,843 shares Net buy direction across all transactions reported in this Form 4

Key Terms

open market transactions, Common Stock, Form 4

3 terms

open market transactions market

"The shares of Common Stock were purchased in several open market transactions"

Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.

Common Stock financial

"The shares of Common Stock were purchased in several open market transactions"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transaction did BIVI report for Joseph M. Palumbo?

BIOVIE INC. reported that Chief Medical Officer Joseph M. Palumbo purchased 4,843 shares of common stock on 2026-08-28 in open market transactions at $2.16 per share, increasing his directly held stake to 6,036 shares.

Was the recent BIVI insider trade a buy or a sell?

The reported BIVI insider trade was a purchase. On 2026-08-28, Chief Medical Officer Joseph M. Palumbo bought 4,843 shares of BIOVIE INC. common stock at $2.16 per share in open market transactions.

At what price did the BIVI insider buy shares on 2026-08-28?

On 2026-08-28, BIOVIE INC. Chief Medical Officer Joseph M. Palumbo bought common stock at $2.16 per share. A footnote states the shares were purchased in several open market transactions, all at the same price, so no weighted average price was reported.

How many BIVI shares does Joseph M. Palumbo hold after this Form 4 transaction?

After the reported transaction, Chief Medical Officer Joseph M. Palumbo directly holds 6,036 shares of BIOVIE INC. common stock, reflecting the addition of 4,843 shares purchased on 2026-08-28.

Were the recent BIVI insider purchases made under a Rule 10b5-1 plan?

The filing for BIOVIE INC. indicates the Rule 10b5-1 trading plan checkbox was not affirmed (aff_10b5_one is false), and the footnote does not reference any trading plan. The purchases are described as several open market transactions at the same price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/28/2026 - 09:02 PM Accepted by SEC EDGAR 08/28/2026 - 09:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Palumbo Joseph M

(Last)

(First)

(Middle)

C/O BIOVIE INC.

680 W NYE LANE STE 201

(Street)

CARSON CITY

NEVADA

89703

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOVIE INC. [ BIVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/28/2026		P		4,843	A	$2.16⁽¹⁾	6,036	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The shares of Common Stock were purchased in several open market transactions, all at the same price. The reported price does not reflect a weighted average price.

	/s/ Joanne Wendy Kim, attorney-in-fact for Joseph M Palumbo, MD	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR